Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MajesTEC-4 maintenance therapy study after autologous stem cell transplant in newly diagnosed multiple myeloma
CTR20251557Phase 3Active
- Sponsor
- Stichting European Myeloma Network/ 杭州泰格医药科技股份有限公司/ Patheon Manufacturing Services LLC
- Start
- May 2025
- Modality
- Small Molecules, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of teclistamab, lenalidomide in multiple myeloma (MM), sponsored by Stichting European Myeloma Network/ 杭州泰格医药科技股份有限公司/ Patheon Manufacturing Services LLC. Started May 2025; status: active.
02
Drugs
teclistamablenalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on CTR20251557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251557.